FindTrial
Sign In

Antidiabetic

DRUG5 trials

Sponsors

Ain Shams University, Federico II University, Jaime Daniel Mondragon, Beni-Suef University

Conditions

Dementia, VascularDiabetesDiabetic NephropathiesHeart FailureMetabolic SyndromeMild Cognitive ImpairmentNon Alcoholic Fatty Liver DiseaseOsteoarthritis

Phase 2

Magnesium Supplementation in Diabetic Nephropathy
CompletedNCT03824379
Ain Shams UniversityDiabetic Nephropathies
Start: 2019-06-01End: 2020-03-01Updated: 2021-01-12
Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients
CompletedNCT03850886
Ain Shams UniversityNon Alcoholic Fatty Liver Disease
Start: 2019-01-15End: 2019-08-07Updated: 2020-01-22
Dapagliflozin Effect in Cognitive Impairment in Stroke Trial
NCT05565976
Jaime Daniel MondragonDementia, Vascular, Metabolic Syndrome, Mild Cognitive Impairment +1
Start: 2020-08-01End: 2025-07-01Target: 270Updated: 2022-10-04

Unknown Phase

Clinical and Echocardiographic Management of Patients With Heart Failure and Diabetes: SCODIAC Follow up Study
CompletedNCT04375943
Federico II UniversityDiabetes, Heart Failure
Start: 2018-04-01End: 2019-09-01Updated: 2020-05-06
GLP1 Analogues and the Risk of Osteoarthritis
Not yet recruitingNCT07360457
Beni-Suef UniversityOsteoarthritis
Start: 2026-02-01End: 2027-03-01Target: 390Updated: 2026-01-22

Related Papers

Impact of magnesium supplementation on clinical outcome and disease progression of patients with diabetic nephropathy: a prospective randomized trial.
2023-12-124 citations
Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial
Therapeutic Advances in Chronic Disease2022-01-0129 citations